Idiopathic Pulmonary Fibrosis Market, By Drug (Pirfenidone, Nintedanib, Others (Interferon gamma-1b and Others)), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Phamacies), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)

Published In : May 2023

Code : CMI2466

Pages :339

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Idiopathic Pulmonary Fibrosis Market- Key Developments

On January 16, 2023, Lotus Pharmaceutical, a multinational pharmaceutical company, announced that the U.S. Food and Drug Administration (U.S. FDA) has granted a tentative approval for the company's abbreviated new drug application (ANDA) for Nintedanib Capsules, the generic version of Boehringer Ingelheim’s OFEV (nintedanib).

In November 2022, Camber Pharmaceuticals, a subsidiary of Hetero, an India-based pharmaceutical company, announced the addition of pirfenidone tablets to their product portfolio that can be used for the treatment of idiopathic pulmonary fibrosis (IPF).

In July 2022, Celix Pharma, a generic medicines manufacturing company, announced the launch of Pirfenidone 267mg, 801mg Film-coated Tablets in the U.K. The 267mg is available in blister packs of 63 and 252 tablets, whereas the 801mg is available in a blister pack of 84 tablets.

In July 2022, PureTech, a biopharmaceutical company, announced that it had initiated a clinical study to evaluate the safety and effectiveness of its experimental therapy LYT-100 in people with idiopathic pulmonary fibrosis (IPF). LYT-100 also called as deupirfenidone is a chemically-modified version of the approved IPF treatment Esbriet (pirfenidone) that is marketed by Genentech, Inc., a biopharmaceutical company.